Singapore company to start clinical safety trials in humans for potential COVID-19 treatment


A Singapore-based company will start human clinical trials next week for a treatment that could slow down the progression of COVID-19 in patients, help them recover faster, and provide temporary protection against the coronavirus.

In a media release on Wednesday (Jun 10), Tychan, a Singapore-based biotechnology company, said it has received approval from the Health Sciences Authority (HSA) for the Phase 1 clinical safety trial in healthy volunteers.

The firm has developed TY027, a monoclonal antibody that specifically targets SARS-CoV-2, the coronavirus that causes COVID-19. Monoclonal antibodies can be isolated and manufactured in large quantities to treat diseases.

Presently, there is no proven antibody-based treatment for COVID-19. There is also no licensed vaccine to prevent SARS-CoV-2 infection, Tychan said. US SPREAD GOOD NEWS!

I run this site in my spare time and thoroughly enjoy giving you all positive news!  If you’ve enjoyed the site we’d love for you to help me share the good news far and wide, share us on Reddit, your Facebook or your Twitter and spread a little positivity around.